Featured Reports, News & Insights.
ICER Finalizes 2023 Updates to Value Assessment Framework
Updates to methods and public meeting procedures reflect experience with previous framework, benchmarking with other HTA groups, and input from external organizations and individuals across the US health system.
09/25/2023ICER Identifies Most Significant 2022 US Drug-Price Hikes Unsupported by New Clinical Evidence
Of 10 high-expenditure drugs that had substantial 2022 net price increases, eight were not supported by new clinical evidence; these increases accounted for $1.27 billion in additional costs over one year.
12/11/2023In Landmark International Program, HTA Agencies Around the World Access ICER’s Customizable COVID-19 Cost-Effectiveness Model
Leveraging ICER’s new cloud-based Interactive Modeler platform, Quebec’s HTA agency has used the COVID-19 model to inform Ministerial recommendations on remdesivir; other HTA agencies and research groups in the United Kingdom, Australia, Canada and South Africa plan to access the model.
10/09/2020